Secondary progressive multiple sclerosis: number of patients and public drug supply in Russia

Ignatyeva V.I.; Derkach E.V.

doi:https://doi.org/10.17116/medtech20214302138

Ignatyeva V.I.

National Center for Healthcare Technology Assessment;
Russian Medical Academy for Continuous Professional Education

Derkach E.V.

National Center for Assessment of Technologies in Healthcare

Secondary progressive multiple sclerosis: number of patients and public drug supply in Russia

Authors:

Ignatyeva V.I., Derkach E.V.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2021;43(2): 38‑43

DOI: 10.17116/medtech20214302138

Read: 1607 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Ignatyeva VI, Derkach EV. Secondary progressive multiple sclerosis: number of patients and public drug supply in Russia. Medical Technologies. Assessment and Choice. 2021;43(2):38‑43. (In Russ.)
https://doi.org/10.17116/medtech20214302138

Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)

Использование инфографики авторами научных работ

Close metadata

Abstract:

OBJECTIVE

To estimate the population of patients with secondary progressive multiple sclerosis (SPMS) and evaluate public drug supply in the Russian Federation.

MATERIAL AND METHODS

The number of SPMS patients was estimated in 61 regions of the Russian Federation. The drug supply, its funding sources and cost of therapy were analyzed in this population.

RESULTS

SPMS patients make up 30.2% of total population of patients with multiple sclerosis (MS), patients with relapsing-remitting MS and confirmed progression outside relapse («possible SPMS») constitute 10.1%. Mean annual cost of disease-modifying therapy is 222.046—268.534 rubles per patient. The main source of funding is federal program of drug supply for patients suffering from so-called expensive diseases.

CONCLUSION

We obtained initial data on the population of patients with SPMS and their drug supply in the Russian Federation. This information can be used optimization of medical and social care (considering a significant limitation of this study — data collection based on survey). Development of a unified information system for monitoring the number of patients with MS, changes in their health status and medical care will significantly improve the quality of available information.

Keywords:

secondary progressive multiple sclerosis

population size estimation

drug supply

Authors:

Ignatyeva V.I.

National Center for Healthcare Technology Assessment;
Russian Medical Academy for Continuous Professional Education

Derkach E.V.

National Center for Assessment of Technologies in Healthcare

Received:

16.03.2021

Accepted:

25.03.2021

Close metadata

References:

Tramacere I, Del Giovane C, Salanti G, D’Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews. 2015;(9):CD011381. https://doi.org/10.1002/14651858.CD011381.pub2
Khurana V, Sharma H, Medin J. Estimated prevalence of secondary progressive multiple sclerosis in the USA and Europe: results from a systematic literature search (P2.380). Neurology. 2018;90(15 suppl):P2.380.
Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D et al.; MSBase Study Group. Defining secondary progressive multiple sclerosis. Brain. 2016;139(Pt 9):2395-2405. https://doi.org/10.1093/brain/aww173
Khurana V, Medin J. Time to, and rate of secondary progression in patients with multiple sclerosis: Results of a systematic search. ECTRIMS Online Library. Medin Journal. 10/25/17; 199347; EP1326. Accessed April 7, 2021. https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/199347/jennie.medin.time.to.and.rate.of.secondary.progression.in.patients.with.html
Yurchenko YuN, Yurchenko AN, Smagina IV. Epidemiology of multiple sclerosis in the Bryansk Region. Nevrologiya, neirop- sikhiatriya, psikhosomatika. 2016;8(3):31-33. (In Russ.).
Alifirova VM, Titova MA, Terskikh EV, Musina NF. Atypical forms of multiple sclerosis in the Tomsk region. Byulleten’ sibirskoj mediciny. 2013;12(5):13-17. (In Russ.). https://doi.org/10.20538/1682-0363-2013-5-13-17
Ivanova EV, Bakhtiyarova KZ, Zaplakhova OV, Sharafutdinova LR. Clinical and epidemiological study of multiple sclerosis in the city of Ufa. Prakticheskaya medicina. 2017;1(1):88-91. (In Russ.).
Khabirov FA, Khaybullin TI, Granatov EV, Averianova LA, Babicheva NN, Sabirov ZhF, et al. Multiple sclerosis in the Republic of Tatarstan: epidemiological and clinical characteristics. Prakticheskaya medicina. 2020;18(5):50-57. (In Russ.). https://doi.org/10.32000/2072-1757-2020-5-50-57
Yagudina RI, Kulikov AYu, Litvinenko MM. Ekonomicheskoe bremya rasseyannogo skleroza. Farmakoekonomika: teoriya i praktika. 2013;1(1):3-34. (In Russ.). https://doi.org/10.30809/phe.1.2013.1
Boyko A, Kobelt G, Berg J, Boyko O, Popova E, Capsa D, et al.; European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia. Multiple Sclerosis. 2017;23(2 suppl):155-165. https://doi.org/10.1177/1352458517708668
Tolkushin AG, Smirnova AV, Davydovskaya MV, Ermolaeva TN, Andreev DA, Kokushkin KA. The burden of multiple sclerosis in Russia and Europe: What’s above? Farmakoekonomika: teoriya i praktika. 2016;6(2):25-30. (In Russ.).
Ivanova EV, Bachtiyarova KZ. Evaluation of economic damage from multiple sclerosis in the city of Ufa, Russia. Farmakoekonomika. Modern Pharmacoeconomic and Pharmacoepidemiology. 2017;10(3):22-27. (In Russ.). https://doi.org/10.17749/2070-4909.2017.10.3.022-027